Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020

• Published in: EJHaem Vol. 4; no. 1; pp. 262 - 265
• Main Authors: Simeunovic, Helena, Dickenmann, Martina, Nabergoj, Mitja, Baldomero, Helen, Masouridi‐Levrat, Stavroula, Nair, Gayathri, Schanz, Urs, Passweg, Jacob, Rovo, Alicia, Chalandon, Yves, Rebmann, Ekaterina
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.02.2023; John Wiley and Sons Inc; Wiley
• Subjects: allogeneic stem cell transplantation; Antigens; Blood diseases; Bone marrow; Conflicts of interest; Data collection; Ethics; Graft versus host disease; Hematopoietic stem cells; Hodgkin lymphoma; Hodgkin's lymphoma; Immune checkpoint inhibitors; Lymphoma; Mortality; Neutrophils; Patients; Remission; Remission (Medicine); Short Report; Short Reports; Stem cell transplantation; Switzerland; allogeneic stem cell transplantation; Hodgkin lymphoma
• ISSN: 2688-6146; 2688-6146
• DOI: 10.1002/jha2.629

Despite the high cure rate with initial therapy, approximately 10% of Hodgkin lymphoma (HL) patients are refractory to initial treatment, and up to 30% of patients will relapse after achieving initial complete remission. Despite promising initial results of treatment by immune checkpoint inhibitors, most patients will eventually progress. We analyzed 62 adult patients with relapsed or refractory HL (rrHL) treated by allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in one of three University Hospitals of Switzerland (Zurich, Basel, and Geneva) between May 2001 and January 2020. The primary endpoint was overall survival (OS). Secondary endpoints were relapse‐free survival (RFS), non‐relapse mortality (NRM), and relapse incidence, which were assessed in univariate analysis. The median follow‐up was 61 months (interquartile range 59–139). The 2‐ and 5‐year OS was 54% (standard error (SE) ±12) and 50.2% (SE ±13.3), respectively, and the 2‐ and 5‐year RFS was 40.7% (SE ±16.3) and 34.4% (SE ±19.0), respectively. NRM was 23.1% (SE ±2.2) and 27.4% (SE ±2.5) at 2 and 5 years, respectively. The cumulative incidence of relapse was 36.1% (SE ±5.6) at 2 years and 38.2% (SE ±6.6) at 5 years. Our analysis of allo‐HSCT outcomes in the context of rrHL shows encouraging OS and RFS rates, with the mortality rate reaching plateau at 50% at 2 years after allo‐HSCT. This confirms that allo‐HSCT still remains as a potentially curative option for half of patients with rrHL.